Welcome to InfiCure Bio
InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.
Based on a panel of in vivo models for these conditions including a proprietary model, the NIF mouse, for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.
Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.
News
Lena Söderström – new Chairman of the Board
InfiCure Bio is pleased to announce that Lena Söderström has been appointed new Chairman of the Board. Lena has longstanding experience from numerous positions in the life science sector and her knowledge, together with her [...]
EASL in Vienna
InfiCure Bio will be present at this years EASL in Vienna. Julia will present the NIF mouse and Dan will talk about imaging in livers of NIF mice. If you're at EASL, do not hesitate [...]
Approved application for “Innovationsprojekt i företag”
InfiCure Bio is happy to announce that the our application for Vinnovas grant "Innovationsprojekt i företag" was funded. In this round of applications, InfiCure Bio was the only company in Västerbotten with an approved application. [...]
New pamphlet on the NIF mouse as a liver fibrosis model
Read our new pamphlet on the NIF mouse as a model for studies of liver fibrosis. The NIF mouse can be used both as a model for tests of drugs to treat general liver fibrosis, [...]